Milan Mrksich

Last updated
Milan Mrksich
Born (1968-08-15) August 15, 1968 (age 56)
Chicago, Illinois
Education University of Illinois at Urbana-Champaign (BS)
California Institute of Technology (PhD)
Known forSAMDI-MS Biochip Technology, Megamolecules
Title
  • Vice President for Research
  • Henry Wade Rogers Professor of Biomedical Engineering at Northwestern University
Awards
  • Camille Dreyfus Teacher-Scholar Award
  • TR100 Innovator Award
  • Arthur C. Cope Scholar Award
  • American Institute for Medical and Biological Engineering
  • Illinois Bio ICON Innovator Awardee
Scientific career
Fields
Institutions
Website Mrksich Group

Milan Mrksich (born 15 August 1968) is an American chemist. He is the Henry Wade Rogers Professor at Northwestern University with appointments in chemistry, biomedical engineering and cell & developmental biology. [1] He also served as both the founding director of the Center for Synthetic Biology and as an associate director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern. [2] [3] Mrksich also served as the Vice President for Research of Northwestern University. [4]

Contents

His research involves the chemistry and synthesis of surfaces that contact biological environments. His laboratory has pioneered several technologies, including strategies to integrate living cells with microelectronic devices, methods to enable high throughput assays for drug discovery, and approaches to making synthetic fusion proteins for applications as therapeutics. Most notably, he developed the SAMDI-MS biochip technology that allows for high-throughput quantification of surface-based biochemical assays using MALDI mass spectrometry. Through SAMDI-MS, Mrksich has become a leader in using label-free technology for drug discovery, founding the company SAMDI Tech in 2011 that primarily serves global pharmaceutical companies. [5] His work has been described in over 240 publications (h-index 98), 500 invited talks, and 18 patents. [6]

Early life and education

Milan Mrksich (Serbian Cyrillic : Милан Мркшић[ citation needed ]) was born on August 15, 1968, to Serbian immigrants and raised in Justice, Illinois. [7] He graduated from University of Illinois at Urbana-Champaign in 1989 with a B.S. in chemistry working in the laboratory of Steven Zimmerman on molecular tweezers. He completed his PhD in organic chemistry in 1994 from Caltech under chemist Peter B. Dervan. After graduate school, he was an American Chemical Society postdoctoral fellow at Harvard University under chemist George M. Whitesides before joining the faculty at the University of Chicago in 1996. He worked there for 15 years before joining the faculty at Northwestern University in 2011. [8]

Research history

Early career

Early on as an independent investigator, Mrksich developed and executed the concept of dynamic substrates for cell culture. Here, self-assembled monolayers (SAMs) present cell adhesive ligands with perfect control over density and orientation against a non-adhesive, inert background, such as ethylene glycol. These monolayers can be further modified with electroactive groups that selectively release immobilized ligand when stimulated with an electric potential. Several strategies using this approach were studied in the context of cell signaling, migration, and co-culture. [9] [10] [11] Subsequent cell-based work focused on developing methods to pattern cells on the aforementioned SAMs. The work has mostly utilized microcontact printing to confine adherent cells into defined positions, shapes, and sizes. Ultimately, his group's work has revealed examples of how cellular mechanics and cytoskeletal structure influence phenotype. A primary example of this involved investigating how cell shape exerts control over the differentiation of mesenchymal stem cells. [12] Further work utilized these patterned monolayers to investigate the relationship between various cytoskeletal elements and to observe complex phenotypic differences in patient-derived neuroprogenitor cells. [13] [14] Recent work in the group investigating cell patterning has utilized photoactive adhesive peptides, allowing for local, spatiotemporal control of cell adhesion to study gap junction formation. [15]

SAMDI-MS

While performing much of the early dynamic substrate and cell patterning work, Mrksich also pioneered an assay platform that utilizes SAMs of alkanethiolates on gold. [16] [17] The monolayers contain capture ligands (e.g. biotin or maleimide) that can selectively immobilize a peptide of interest. Subsequently, the monolayer can treated with a specific enzyme or a complex mixture, such as cell lysate, that can modify the peptide through various biological processes (e.g. phosphorylation). For quality control, the monolayers present these peptides against a background of tri(ethylene glycol) groups to prevent the nonspecific adsorption of protein to the surface that could obfuscate the reaction signal and, therefore, enable quantitative and reproducible assays. Most significantly, the monolayers can be characterized with MALDI mass spectrometry in a technique known as SAMDI-MS, which provides the masses of the substituted alkanethiolates and, therefore, the mass change of the immobilized peptide that results from enzyme activity. The method is compatible with standard array formats and liquid handling robotics, allowing a throughput in the tens of thousands of reactions per day. Importantly, the matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF) analysis provides a fast and quantitative mass shift readout without the need for labels.

Megamolecules

Most recently, Mrksich's group has focused on developing a technique for assembling large molecular structures with perfectly defined structures and orientations, known as Megamolecules. This is primarily done through use of fusion proteins and irreversible inhibitor linkers that assemble stable intermediates. [18] Structure-function relationships, including synthesis of cyclic and antibody-mimic structures have been investigated for potential therapeutic application. [19] [20]

Entrepreneurship

Mrksich has been an active entrepreneur over the past twenty years.  He co-founded SAMDI Tech in 2011, which uses his label-free assay technology to perform high throughput screens for pharmaceutical companies.  SAMDI Tech entered into a partnership with Charles River Laboratories in 2018 and was purchased by CRL in 2023. [21] [22]   Mrksich also co-founded WMR Biomedical in 2008, with George Whitesides and Carmichael Roberts to develop resorbable stent materials; this company was renamed Lyra Therapeutics and had an IPO in 2020 (NASDAQ LYRA) and has drug-eluting stents in clinical trials for ear, nose and throat disease, including chronic rhinosinusitis. [23] Mrksich has recently founded ModuMab Therapeutics, which applies his megamolecule technology to creating antibody mimics for a broad range of diseases.

Service

Mrksich has also been active in serving the scientific community in a number of roles.  These include his current service as the Scientific Director [24] of the Searle Scholars Program, as a member of the Board of Governors [25] for Argonne National Laboratory, and as a member of the Board of Directors [26] for the Camille & Henry Dreyfus Foundation.  His past appointments include service and chairing DARPA’s Defense Sciences Research Council and many program advisory committees.

Awards and honors

Personal life

Milan lives in Hinsdale, Illinois with his two children.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Proteomics</span> Large-scale study of proteins

Proteomics is the large-scale study of proteins. Proteins are vital macromolecules of all living organisms, with many functions such as the formation of structural fibers of muscle tissue, enzymatic digestion of food, or synthesis and replication of DNA. In addition, other kinds of proteins include antibodies that protect an organism from infection, and hormones that send important signals throughout the body.

Glycomics is the comprehensive study of glycomes, including genetic, physiologic, pathologic, and other aspects. Glycomics "is the systematic study of all glycan structures of a given cell type or organism" and is a subset of glycobiology. The term glycomics is derived from the chemical prefix for sweetness or a sugar, "glyco-", and was formed to follow the omics naming convention established by genomics and proteomics.

<span class="mw-page-title-main">Electrospray ionization</span> Technique used in mass spectroscopy

Electrospray ionization (ESI) is a technique used in mass spectrometry to produce ions using an electrospray in which a high voltage is applied to a liquid to create an aerosol. It is especially useful in producing ions from macromolecules because it overcomes the propensity of these molecules to fragment when ionized. ESI is different from other ionization processes since it may produce multiple-charged ions, effectively extending the mass range of the analyser to accommodate the kDa-MDa orders of magnitude observed in proteins and their associated polypeptide fragments.

<span class="mw-page-title-main">Aptamer</span> Oligonucleotide or peptide molecules that bind specific targets

Aptamers are oligomers of artificial ssDNA, RNA, XNA, or peptide that bind a specific target molecule, or family of target molecules. They exhibit a range of affinities, with variable levels of off-target binding and are sometimes classified as chemical antibodies. Aptamers and antibodies can be used in many of the same applications, but the nucleic acid-based structure of aptamers, which are mostly oligonucleotides, is very different from the amino acid-based structure of antibodies, which are proteins. This difference can make aptamers a better choice than antibodies for some purposes.

<span class="mw-page-title-main">Peptide mass fingerprinting</span> Analytical technique for protein identification

Peptide mass fingerprinting (PMF), also known as protein fingerprinting, is an analytical technique for protein identification in which the unknown protein of interest is first cleaved into smaller peptides, whose absolute masses can be accurately measured with a mass spectrometer such as MALDI-TOF or ESI-TOF. The method was developed in 1993 by several groups independently. The peptide masses are compared to either a database containing known protein sequences or even the genome. This is achieved by using computer programs that translate the known genome of the organism into proteins, then theoretically cut the proteins into peptides, and calculate the absolute masses of the peptides from each protein. They then compare the masses of the peptides of the unknown protein to the theoretical peptide masses of each protein encoded in the genome. The results are statistically analyzed to find the best match.

<span class="mw-page-title-main">Matrix-assisted laser desorption/ionization</span> Ionization technique

In mass spectrometry, matrix-assisted laser desorption/ionization (MALDI) is an ionization technique that uses a laser energy-absorbing matrix to create ions from large molecules with minimal fragmentation. It has been applied to the analysis of biomolecules and various organic molecules, which tend to be fragile and fragment when ionized by more conventional ionization methods. It is similar in character to electrospray ionization (ESI) in that both techniques are relatively soft ways of obtaining ions of large molecules in the gas phase, though MALDI typically produces far fewer multi-charged ions.

The terms glycans and polysaccharides are defined by IUPAC as synonyms meaning "compounds consisting of a large number of monosaccharides linked glycosidically". However, in practice the term glycan may also be used to refer to the carbohydrate portion of a glycoconjugate, such as a glycoprotein, glycolipid, or a proteoglycan, even if the carbohydrate is only an oligosaccharide. Glycans usually consist solely of O-glycosidic linkages of monosaccharides. For example, cellulose is a glycan composed of β-1,4-linked D-glucose, and chitin is a glycan composed of β-1,4-linked N-acetyl-D-glucosamine. Glycans can be homo- or heteropolymers of monosaccharide residues, and can be linear or branched.

Surface-enhanced laser desorption/ionization (SELDI) is a soft ionization method in mass spectrometry (MS) used for the analysis of protein mixtures. It is a variation of matrix-assisted laser desorption/ionization (MALDI). In MALDI, the sample is mixed with a matrix material and applied to a metal plate before irradiation by a laser, whereas in SELDI, proteins of interest in a sample become bound to a surface before MS analysis. The sample surface is a key component in the purification, desorption, and ionization of the sample. SELDI is typically used with time-of-flight (TOF) mass spectrometers and is used to detect proteins in tissue samples, blood, urine, or other clinical samples, however, SELDI technology can potentially be used in any application by simply modifying the sample surface.

Soft laser desorption (SLD) is laser desorption of large molecules that results in ionization without fragmentation. "Soft" in the context of ion formation means forming ions without breaking chemical bonds. "Hard" ionization is the formation of ions with the breaking of bonds and the formation of fragment ions.

<span class="mw-page-title-main">MALDI imaging</span> Imaging system

MALDI mass spectrometry imaging (MALDI-MSI) is the use of matrix-assisted laser desorption ionization as a mass spectrometry imaging technique in which the sample, often a thin tissue section, is moved in two dimensions while the mass spectrum is recorded. Advantages, like measuring the distribution of a large amount of analytes at one time without destroying the sample, make it a useful method in tissue-based study.

<span class="mw-page-title-main">Protein mass spectrometry</span> Application of mass spectrometry

Protein mass spectrometry refers to the application of mass spectrometry to the study of proteins. Mass spectrometry is an important method for the accurate mass determination and characterization of proteins, and a variety of methods and instrumentations have been developed for its many uses. Its applications include the identification of proteins and their post-translational modifications, the elucidation of protein complexes, their subunits and functional interactions, as well as the global measurement of proteins in proteomics. It can also be used to localize proteins to the various organelles, and determine the interactions between different proteins as well as with membrane lipids.

<span class="mw-page-title-main">Top-down proteomics</span>

Top-down proteomics is a method of protein identification that either uses an ion trapping mass spectrometer to store an isolated protein ion for mass measurement and tandem mass spectrometry (MS/MS) analysis or other protein purification methods such as two-dimensional gel electrophoresis in conjunction with MS/MS. Top-down proteomics is capable of identifying and quantitating unique proteoforms through the analysis of intact proteins. The name is derived from the similar approach to DNA sequencing. During mass spectrometry intact proteins are typically ionized by electrospray ionization and trapped in a Fourier transform ion cyclotron resonance, quadrupole ion trap or Orbitrap mass spectrometer. Fragmentation for tandem mass spectrometry is accomplished by electron-capture dissociation or electron-transfer dissociation. Effective fractionation is critical for sample handling before mass-spectrometry-based proteomics. Proteome analysis routinely involves digesting intact proteins followed by inferred protein identification using mass spectrometry (MS). Top-down MS (non-gel) proteomics interrogates protein structure through measurement of an intact mass followed by direct ion dissociation in the gas phase.

<span class="mw-page-title-main">ALCAM</span> Protein-coding gene in the species Homo sapiens

CD166 antigen is a 100-105 kD typeI transmembrane glycoprotein that is a member of the immunoglobulin superfamily of proteins. In humans it is encoded by the ALCAM gene. It is also called CD166, MEMD, SC-1/DM-GRASP/BEN in the chicken, and KG-CAM in the rat.

Kevin Downard is a British - Australian academic scientist whose research specialises in the improving responses to infectious disease through the application and development of mass spectrometry and other molecular approaches in the life and medical sciences. Downard has over 35 years of experience in the field and has written 150 lead-author scientific peer-reviewed journal publications, and two books including a textbook for the Royal Society of Chemistry and the first book to be published on the role of mass spectrometry in the study of protein interactions.

<span class="mw-page-title-main">Desorption/ionization on silicon</span> Soft laser desorption method

Desorption/ionization on silicon (DIOS) is a soft laser desorption method used to generate gas-phase ions for mass spectrometry analysis. DIOS is considered the first surface-based surface-assisted laser desorption/ionization (SALDI-MS) approach. Prior approaches were accomplished using nanoparticles in a matrix of glycerol, while DIOS is a matrix-free technique in which a sample is deposited on a nanostructured surface and the sample desorbed directly from the nanostructured surface through the adsorption of laser light energy. DIOS has been used to analyze organic molecules, metabolites, biomolecules and peptides, and, ultimately, to image tissues and cells.

Chemoproteomics entails a broad array of techniques used to identify and interrogate protein-small molecule interactions. Chemoproteomics complements phenotypic drug discovery, a paradigm that aims to discover lead compounds on the basis of alleviating a disease phenotype, as opposed to target-based drug discovery, in which lead compounds are designed to interact with predetermined disease-driving biological targets. As phenotypic drug discovery assays do not provide confirmation of a compound's mechanism of action, chemoproteomics provides valuable follow-up strategies to narrow down potential targets and eventually validate a molecule's mechanism of action. Chemoproteomics also attempts to address the inherent challenge of drug promiscuity in small molecule drug discovery by analyzing protein-small molecule interactions on a proteome-wide scale. A major goal of chemoproteomics is to characterize the interactome of drug candidates to gain insight into mechanisms of off-target toxicity and polypharmacology.

Stable isotope standards and capture by anti-peptide antibodies (SISCAPA) is a mass spectrometry method for measuring the amount of a protein in a biological sample.

Peter Nemes is a Hungarian-American chemist, who is active in the fields of bioanalytical chemistry, mass spectrometry, cell/developmental biology, neuroscience, and biochemistry.

<span class="mw-page-title-main">Gerardo Turcatti</span> Swiss-Uruguayan chemical biologist and pharmacologist

Gerardo Turcatti is a Swiss-Uruguayan chemist who specialises in chemical biology and drug discovery. He is a professor at the École Polytechnique Fédérale de Lausanne (EPFL) and director of the Biomolecular Screening Facility at the School of Life Sciences there.

Amy M. Barrios is an American medicinal chemist working as a professor of Medicinal Chemistry and the Associate Dean for Postdoctoral Affairs for the University of Utah. Barrios' research lab focuses on developing probes to study protein tyrosine phosphatase (PTP) activity and regulation.

References

  1. ↑ Northwestern University. "Professor Milan Mrksich". McCormick School of Engineering.
  2. ↑ Northwestern University. "Center for Synthetic Biology".
  3. ↑ Northwestern University. "Robert H. Lurie Comprehensive Cancer Center of Northwestern University". Feinberg School of Medicine.
  4. ↑ Samuelson, Kristin (2020). "Milan Mrksich named Northwestern's Vice President for Research". Northwestern Now.
  5. ↑ SAMDI Tech. "About SAMDI Tech".
  6. ↑ Google Scholar. "Milan Mrksich Publishing Record".{{cite web}}: |author= has generic name (help)
  7. ↑ "This drug-testing lab is speed-of-light fast". 16 July 2014.
  8. ↑ United States House of Representatives. "Milan Mrksich Biographical Sketch" (PDF).
  9. ↑ Yousaf, M.N.; Houseman, B.T.; Mrksich, M. (2001). "Turning on Cell Migration with Electroactive Substrates". Angew. Chem. Int. Ed. 40 (6): 1093–1096. doi:10.1002/1521-3773(20010316)40:6<1093::aid-anie10930>3.3.co;2-h.
  10. ↑ Hodneland, C.D.; Mrksich, M. (2000). "Biomolecular Surfaces that Release Ligands Under Electrochemical Control". J. Am. Chem. Soc. 122 (17): 4235–4236. doi:10.1021/ja000419p.
  11. ↑ Yousaf, M.N.; Houseman, B.T.; Mrksich, M. (2001). "Using Electroactive Substrates to Pattern the Attachment of Two Different Cell Types". Proc. Natl. Acad. Sci. 98 (11): 5992–5996. doi: 10.1073/pnas.101112898 . PMC   33411 . PMID   11353818.
  12. ↑ Kilian, K.A.; Bugarija, B.; Lahn, B.T.; Mrksich, M. (2001). "Geometric Cues for Directing the Differentiation of Mesenchymal Stem Cells". Proc. Natl. Acad. Sci. 107 (11): 4872–4877. doi: 10.1073/pnas.0903269107 . PMC   2841932 . PMID   20194780.
  13. ↑ Shabbir, S.H.; Cleland, R.D.; Goldman, R.D.; Mrksich, M. (2014). "Geometric Control of Cytoskeletal Elements: Impact on Vimentin Intermediate Filaments". Biomaterials. 35 (5): 1359–1366. doi:10.1016/j.biomaterials.2013.10.008. PMC   3875369 . PMID   24268665.
  14. ↑ Brennand, J.N.; et, al. (2014). "Geometric Control of Cytoskeletal Elements: Impact on Vimentin Intermediate Filaments". Mol. Psych.: 1–8.
  15. ↑ Bugga, P.; Mrksich, M. (2019). "Sequential Photoactivation of Self-Assembled Monolayers to Direct Cell Adhesion and Migration". Langmuir . 35 (17): 5937–5943. doi:10.1021/acs.langmuir.8b04203. PMC   8262134 . PMID   30943037.
  16. ↑ Houseman, B.T.; Huh, J.H.; Kron, S.J.; Mrksich, M. (2002). "Peptide Chips for the Evaluation of Protein Kinase Activity". Nature Biotechnology. 20 (3): 270–274. doi:10.1038/nbt0302-270. PMID   11875428. S2CID   18043752.
  17. ↑ Su, J.; Mrksich, M. (2002). "Using Mass Spectrometry to Characterize Self-Assembled Monolayers Presenting Peptides, Proteins and Carbohydrates". Angew. Chem. Int. Ed. 41 (24): 4715–4718. doi:10.1002/anie.200290026. PMID   12481336.
  18. ↑ Modica, J.A.; Skarpathiotis, S.; Mrksich, M. (2012). "Modular Assembly of Protein Building Blocks to Create Precisely-Defined MegaMolecules". ChemBioChem. 13 (16): 2331–2334. doi:10.1002/cbic.201200501. PMC   3804166 . PMID   23070998.
  19. ↑ Modica, J.A.; Lin, Y.; Mrksich, M. (2018). "Synthesis of Cyclic Megamolecules". J. Am. Chem. Soc. 140 (20): 6391–6399. doi:10.1021/jacs.8b02665. PMID   29723476. S2CID   13688765.
  20. ↑ Taylor, E.L.; Metcalf, K.J.; Carlotti, B.; Lai, C.-T.; Modica, J.A.; Schatz, G.C.; Mrksich, M.; Goodson, T. (2018). "Long-Range Energy Transfer in Protein Megamolecules". J. Am. Chem. Soc. 140 (46): 15731–15743. doi:10.1021/jacs.8b08208. PMC   6710013 . PMID   30375862.
  21. ↑ "Charles River Expands Strategic Partnership With SAMDI Tech | Charles River Laboratories International, Inc". ir.criver.com. Retrieved 2022-05-25.
  22. ↑ "Drug discovery startup spun out of Northwestern acquired for $50 million". Crain's Chicago Business. 2023-01-30. Retrieved 2023-02-10.
  23. ↑ "Lyra Therapeutics Announces Pricing of Initial Public Offering". www.businesswire.com. 2020-05-01. Retrieved 2022-05-25.
  24. ↑ "Advisory Council". 2022-06-09. Retrieved 2022-09-20.
  25. ↑ "Board of Governors | UChicago Argonne LLC". www.uchicagoargonnellc.org. Retrieved 2022-09-20.
  26. ↑ "About Us". Dreyfus Foundation. Retrieved 2022-09-20.
  27. ↑ "Awards and honors". 25 May 2022.
  28. ↑ "Mrksich elected to board". 26 May 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.